Shop by goal

Popular compounds

Research resources

Recently viewed

Semaglutide: A Research Guide to the GLP-1 Single Agonist

Short answer: semaglutide is a 31-amino-acid synthetic peptide developed by Novo Nordisk, the modified GLP-1 backbone behind Ozempic (type-2 diabetes), Wegovy (chronic weight management) and Rybelsus (oral form). It is a single GLP-1 receptor agonist with a half-life of roughly 7 days, supporting once-weekly subcutaneous administration. The pivotal STEP programme reported mean weight reductions of ~14.9% over 68 weeks at the 2.4 mg dose. New-U catalogues research-grade semaglutide as Semaglutide - lyophilised reference peptide, sealed vials, per-batch CoA, research use only.

Semaglutide is the molecule that turned “GLP-1” into a household acronym. With roughly 550,000 monthly Google searches in the United States alone , it sits just behind tirzepatide in the incretin-class search landscape, and remains the reference single-agonist for any GLP-1 comparison - head-to-head trials use semaglutide as the active comparator because it is the established standard. This guide explains what the molecule is, what the STEP and SUSTAIN trials actually showed, how injectable and oral forms relate, and how research-grade semaglutide sits on the New-U catalogue as Semaglutide. For the gateway explainer aimed at people who arrived via a search for “is Ozempic a peptide?”, start with Is Ozempic a Peptide?; for the single-vs-dual comparison see Semaglutide vs Tirzepatide.

Plain-English summary. Semaglutide is an approved medicine in the United States, the United Kingdom and many other jurisdictions when supplied through licensed channels as Ozempic, Wegovy or Rybelsus. Research-grade semaglutide, sold as a lyophilised reference peptide for laboratory use, is a separate non-medicine category. New-U sells only the research reagent - not the medicine - with no human-use claims, no dosing guidance and no therapeutic protocol. This page is general information, not legal or medical advice.

What semaglutide actually is

Semaglutide is a 31-amino-acid analogue of human glucagon-like peptide-1 (GLP-1). The molecule borrows the GLP-1(7–37) backbone and makes three engineering changes: an Aib substitution at position 8 to block DPP-4 cleavage, an arginine at position 34 , and a C18 fatty di-acid conjugated to Lys26 via a γ-Glu-2xOEG linker. The fatty di-acid drives reversible albumin binding; albumin binding is what extends the circulating half-life from native GLP-1’s ~2 minutes to semaglutide’s ~7 days.

The result is a selective GLP-1 receptor agonist - no off-target GIP or glucagon activity - with pharmacokinetics that support a single weekly subcutaneous injection. The full mechanism is reviewed in the StatPearls semaglutide chapter.

Mechanism of action, in plain English

GLP-1 receptor agonism produces a cluster of overlapping effects:

What semaglutide does not do, in contrast to tirzepatide and retatrutide, is activate the GIP or glucagon receptors. That is the single mechanistic line separating it from the dual and triple agonists.

The clinical evidence: STEP, SUSTAIN and SELECT

Semaglutide has the deepest Phase 3 evidence base of any peptide in the incretin class:

SUSTAIN (type-2 diabetes, 10 trials). Reported HbA1c reductions of ~1.5–1.8% from baseline at the 1.0 mg weekly dose, superior to comparators across the programme including sitagliptin (SUSTAIN-2), exenatide (SUSTAIN-3) and insulin glargine (SUSTAIN-4).

STEP (chronic weight management, 8 trials). STEP-1 (NEJM, 2021) reported mean body-weight reduction of ~14.9% over 68 weeks at the 2.4 mg dose in adults with obesity without diabetes, vs ~2.4% for placebo. The 2.4 mg dose became the basis for the Wegovy approval.

SELECT (cardiovascular outcomes). Demonstrated a significant reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease - the first GLP-1 outcomes trial in a non-diabetic population, and the evidence behind the 2024 cardiovascular-protection label expansion.

Injectable vs oral semaglutide

Semaglutide is the only GLP-1 agonist with an approved oral formulation (Rybelsus). The molecule is the same; the formulation is the difference. Rybelsus co-formulates semaglutide with SNAC (sodium N-(8-(2-hydroxybenzoyl) amino) caprylate), an absorption enhancer that transiently raises gastric pH and disrupts the gastric mucosal barrier just long enough to allow the peptide to cross.

Oral bioavailability is around 0.4–1.0% , which is why oral doses (7–14 mg daily) are an order of magnitude higher than injectable doses (0.25–2.4 mg weekly). Oral semaglutide must be taken on an empty stomach with no more than 120 mL of water, with at least 30 minutes elapsed before any other oral intake, or absorption collapses.

Semaglutide vs tirzepatide vs retatrutide

The full incretin landscape:

In the SURMOUNT-5 head-to-head (NEJM, 2025), tirzepatide produced a significantly greater mean reduction in body weight than semaglutide over 72 weeks. Semaglutide remains the more-studied molecule and the only one with a cardiovascular outcomes trial in a non-diabetic obese population.

Semaglutide as a research compound

On the New-U catalogue, the research-grade reference peptide is listed as Semaglutide . Same 31-amino-acid sequence, same selective GLP-1 receptor mechanism, same molecule that Novo Nordisk supplies to pharmacies as Ozempic, Wegovy or Rybelsus, supplied here as a research compound alongside our wider incretin reference range (semaglutide, tirzepatide and retatrutide).

How to verify semaglutide purity

For a 31-amino-acid lipidated peptide, the purity questions are:

Full walkthrough: How to Read a Certificate of Analysis.

Red flags on semaglutide listings

The semaglutide search surface is one of the most counterfeited in the entire peptide market. Walk away from any listing that:

Storage & handling of lyophilised semaglutide

Lyophilised semaglutide is stable at −20°C for long-term storage; sealed vials tolerate brief excursions during shipment. Allow vials to warm to room temperature before opening to avoid condensation entering the vial. Once reconstituted, store at 2–8°C and protect from light; reconstituted material is best used within a research-relevant time window appropriate to the stability data you have on hand. Full reference: How to Store Peptides. For reconstitution volume calculation, our reconstitution calculator handles the mg-to-mL maths for any vial size.

Frequently Asked Questions

What is semaglutide? A 31-amino-acid synthetic peptide and a selective GLP-1 receptor agonist developed by Novo Nordisk. Approved as Ozempic (type-2 diabetes), Wegovy (chronic weight management) and Rybelsus (oral form).

How long is semaglutide’s half-life? Approximately 165 hours (~7 days) for the injectable form, supporting once-weekly dosing. Driven by a C18 fatty di-acid that reversibly binds albumin.

Is oral semaglutide the same molecule as injectable? Yes - Rybelsus is the same semaglutide molecule, co-formulated with the absorption enhancer SNAC to allow gastric uptake. Oral bioavailability is roughly 0.4–1.0%, which is why oral doses are an order of magnitude higher than injectable.

How is semaglutide different from tirzepatide? Semaglutide is a single GLP-1 agonist. Tirzepatide is a dual GLP-1 + GIP agonist. In SURMOUNT-5 (NEJM, 2025) tirzepatide produced a greater mean weight reduction over 72 weeks.

Is semaglutide a research compound on this site? Yes. New-U catalogues research-grade semaglutide as Semaglutide, lyophilised reference peptide with a per-batch Certificate of Analysis. Sold research use only, not for human consumption.

Related Reading

Primary sources & further reading

External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way. Ozempic, Wegovy and Rybelsus are trade names of Novo Nordisk; New-U sells research-grade reference peptide only, not the licensed medicine.

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Research Semaglutide

New-U Research Compounds catalogues semaglutide as Semaglutide - sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Tracked worldwide delivery. Research use only - not for human consumption.

Research-grade · >99% HPLC purity · COA per lot

Buy Semaglutide from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Shop

Learn

Company

Support

Ways to Pay

Shop by Compound

Shop by Goal

Ships worldwide

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

© 2026 New-U Research Compounds · new-u.io · @new.u.io